Company intelligence / Profile preview
Neuroene Therapeutics
South Carolina, United Statesneuroenetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Neuroene Therapeutics has developed compounds that show efficacy in animal models of epilepsy and Parkinson's disease. Their lead candidate for Dravet syndrome has received FDA Orphan Drug Designation and has shown efficacy as both monotherapy and adjunct therapy in animal seizure models.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Johnson & Johnson Innovation (JLABS)
Beyond the preview
Go deeper on Neuroene Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuroene Therapeutics.